Navigating preclinical peptide acquisition demands strict technical compliance, verifiable purity metrics, and complete batch traceability. As a leading bronchogen rat model professional manufacturer, PX1 Research provides high-purity research compounds backed by independent analytical verification for rigorous laboratory investigations. All products are supplied strictly for in vitro and preclinical research applications.
Navigating preclinical peptide acquisition demands strict technical compliance, verifiable purity metrics, and complete batch traceability. As a leading bronchogen rat model professional manufacturer, PX1 Research provides high-purity research compounds backed by independent analytical verification for rigorous laboratory investigations. All products are supplied strictly for in vitro and preclinical research applications.
A professional manufacturer supplying Bronchogen for rat models must provide synthetic peptides with verified primary sequence identity, high chromatographic purity (≥98% by RP-HPLC), minimal endotoxin content (<0.01 EU/µg), and lot-specific mass spectrometry validation. PX1 Research manufactures research-grade Bronchogen in ISO 17025-accredited, GMP-compliant US facilities to ensure consistent baseline data in preclinical pulmonary and respiratory research.
When designing animal experiments, research teams require compounds that demonstrate batch-to-batch consistency. Variances in residual counter-ions, trifluoroacetic acid (TFA) salt concentrations, or baseline bacterial endotoxins can significantly skew cellular responses and systemic inflammatory markers in rodent models. Selecting an established manufacturer guarantees that experimental observations reflect the inherent bioactivity of the peptide rather than synthetic contaminants or degraded reagents.
Bronchogen is a synthetic tetrapeptide consisting of the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu or AEDL). Belonging to the class of short-chain peptide bioregulators, Bronchogen exhibits a molecular weight of approximately 446.45 g/mol. Its hydrophilic core and net negative charge at physiological pH influence its solubility, receptor interaction kinetics, and passive diffusion characteristics in biological matrix testing.
In laboratory settings, short-chain peptides like Bronchogen offer specific structural advantages over larger native proteins. Their low molecular weight allows for enhanced tissue penetration in organ bath assays and cell culture matrices, while reducing non-specific protein binding. To explore related short-chain regulatory peptides, investigators can examine our complete directory of research peptides available for comparative laboratory evaluation.
Preclinical studies suggest that Bronchogen interacts with gene expression profiles within bronchial and pulmonary epithelial tissues. In vitro assays using primary bronchial epithelial cell cultures indicate that the tetrapeptide may modulate chromatin conformation, influencing the transcription of structural proteins and cytokines involved in mucosal integrity.
In rodent models, particularly rat models of induced pulmonary inflammation, researchers utilize Bronchogen to investigate markers of oxidative stress, surfactant protein regulation, and inflammatory cell infiltration. In vitro data indicate that exposure to Bronchogen can alter the expression of pro-inflammatory cytokines such as TNF-alpha and IL-6 in pulmonary macrophage models, offering insights into homeostatic repair pathways without altering underlying genomic DNA.
In vivo rodent models evaluating respiratory pathophysiology frequently incorporate Bronchogen to assess tissue remodeling and bronchial reactivity. Protocols typically involve acute or chronic lung injury models induced by lipopolysaccharide (LPS) exposure, cigarette smoke extracts, or toxic chemical irritants. Researchers measure physiological parameters including airway resistance, dynamic compliance, and histological remodeling scores.
Establishing consistent baseline metrics across cohorts requires identical peptide mass, purity, and salt formulations. A specialized bronchogen rat model professional manufacturer ensures that every vial delivers exact stoichiometric ratios, allowing investigators to accurately correlate dosage parameters with biological end-points in respiratory research.
When evaluating respiratory, mucosal, and cellular repair pathways, researchers frequently compare Bronchogen against other synthetic research compounds targeting inflammatory or regenerative cascades. Understanding the functional distinction between these peptides is critical when designing multi-arm preclinical protocols.
While Bronchogen specifically targets gene expression and mucosal homeostatic pathways in lung tissue models, compounds like BPC-157 are widely studied for cytoprotective and angiogenic signaling across gastrointestinal and musculoskeletal models. Similarly, the tripeptide KPV is primarily evaluated for its anti-inflammatory interactions via nuclear factor kappa B (NF-κB) pathways in dermal and intestinal models, whereas TB-500 (Thymosin Beta-4 fragment) focuses on actin sequestration and cell migration dynamics. Integrating these distinct peptides allows laboratories to delineate specific pathway contributions in complex systemic inflammation assays.
High-performance liquid chromatography (RP-HPLC) and matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF MS) represent the gold standard for peptide verification. As an established USA manufacturer, PX1 Researchsubjects every production lot of Bronchogen to rigorous dual-testing protocols to ensure chemical identity and quantitative purity.
A authentic Certificate of Analysis (COA) must accompany every lot, explicitly detailing exact retention times, mass-to-charge ratios (m/z), and purity percentages. Laboratories sourcing compounds through our wholesale research account portal receive full, unredacted analytical documentation per lot, ensuring full compliance with institutional audit standards and publication guidelines.
Bacterial endotoxins, predominantly lipopolysaccharides (LPS) derived from Gram-negative outer membranes, pose a significant risk to rodent respiratory models. Elevated endotoxin levels in research compounds can trigger unmeasured inflammatory cascades, invalidating immunological markers and confusing primary research endpoints.
PX1 Research enforces stringent endotoxin limits on all research-grade peptides, utilizing Chromogenic Limulus Amebocyte Lysate (LAL) testing to verify levels strictly below 0.01 EU/µg. Lyophilized vials are processed in ISO Class 5 cleanrooms within GMP-compliant facilities, preventing exogenous contamination and providing reliable substrates for sensitive in vivo and ex vivo assays.
Proper reconstitution of lyophilized Bronchogen is critical to maintaining peptide stability and preventing aggregation. Laboratories should utilize sterile, bacteriostatic water or phosphate-buffered saline (PBS, pH 7.4) depending on the requirements of the downstream assay. Reconstitution should occur in a laminar flow cabinet using aseptic technique.
To reconstitute, allow the vial to equilibrate to room temperature before adding the sterile solvent down the inner glass wall. Gently swirl the vial until the cake is fully dissolved; avoid vigorous vortexing, which can introduce shear stress and cause peptide denaturation. Stock solutions should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles. Detailed handling guidelines can be explored further in the PX1 Research documentation hub.
Lyophilized Bronchogen remains stable at -20°C for up to 24 months when protected from light and moisture. For long-term archival storage, maintaining vials at -80°C minimizes chemical degradation, such as aspartic acid isomerization or peptide bond hydrolysis.
Once reconstituted into aqueous solution, short-chain peptides are inherently more susceptible to enzymatic degradation and hydrolysis. Sterile liquid aliquots stored at 4°C should be used within 7 to 14 days. If long-term liquid storage is necessary, freezing aliquots at -80°C is recommended, taking care to minimize temperature fluctuations during storage cycles.
Preclinical research timelines rely on dependable supply chains and rapid fulfillment. PX1 Research operates state-of-the-art dispatch hubs located in California and Arizona, facilitating same-day shipping for orders placed before 3:00 PM EST, Monday through Friday.
All shipments are packaged in climate-controlled, insulated containers to protect lyophilized peptide integrity against ambient temperature extremes during transit. By maintaining domestic US manufacturing and distribution, PX1 Research eliminates customs delays and ensures continuous inventory availability for academic, biopharmaceutical, and contract research organizations worldwide.
What is Bronchogen used for in laboratory research?
Bronchogen (Ala-Glu-Asp-Leu) is studied as a research-grade peptide bioregulator in preclinical models to evaluate bronchial cell function, tissue remodeling, mucosal homeostasis, and inflammatory pathways in rodent pulmonary models.
Why is supplier selection critical for Bronchogen rat model research?
Selecting a verified manufacturer ensures that the compound lacks endotoxin contamination, TFA residue excess, or synthesis impurities that could confound immunological and histological data in rodent models.
What purity level does PX1 Research guarantee for Bronchogen?
PX1 Research guarantees a minimum purity of 98% for Bronchogen, verified by lot-specific Reverse-Phase HPLC and Mass Spectrometry analysis.
How should lyophilized Bronchogen be stored upon arrival?
Lyophilized Bronchogen should be stored at -20°C for standard short-to-medium term research needs, or at -80°C for long-term storage, protected from light and moisture.
What liquid solvents are recommended for reconstituting Bronchogen?
Sterile Bacteriostatic Water, Sterile Water for Injection, or sterile Phosphate-Buffered Saline (PBS, pH 7.4) are typically recommended depending on the specific in vitro or animal model protocol.
Are batch-specific Certificates of Analysis provided with orders?
Yes, every batch of Bronchogen shipped by PX1 Research includes a comprehensive, lot-specific COA containing full HPLC chromatograms, mass spec reports, and endotoxin assay results.
What is the endotoxin limit for PX1 Research Bronchogen?
PX1 Research enforces strict endotoxin controls, ensuring levels test below 0.01 EU/µg using standardized LAL methodology to prevent non-specific immune responses in laboratory models.
Can Bronchogen be used for clinical or therapeutic applications in humans?
No. Bronchogen provided by PX1 Research is strictly designated for laboratory research use only (RUO) and in vitro or preclinical animal investigations. It is not for human or veterinary medical use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.